Repair Biotechnologies

11/25/2025

AHA 2025 Recap: People are shutting off the water, but NO ONE is draining the sink.

The core data highlighted at the 2025 American Heart Association (AHA) Annual Meeting was focused on the positive outcomes from some of the LDL lowering therapies such as Merck’s Enlicitide. While these ARE positive data points, the unfortunate truth is NONE of these are tackling the root cause of cardiovascular related events, plaque buildup.

At Repair Biotechnologies, our focus is on PLAQUE REGRESSION and significant reduction of the plaque that, when ruptured, causes these significant cardiovascular related events, such as heart attack or stroke. And while these LDL lowering therapies do slow down the buildup of plaque, they have yet to meaningfully show plaque regression which means patients are still at risk if when their LDL is lowered (i.e. they are turning off the water, but not draining the sink).

IF YOU ARE INTERESTED to learn how Repair Biotechnologies is ‘draining the sink’, we invite you to not only visit our website, but also, sign up below to be added to our direct distribution where you can receive periodic updates as we continue to advance our lead candidates, REP-0003 and REP-0004, and as we aim to provide a TRULY CURATIVE SOLUTION for those at risk.

LEARN MORE NOW! https://loom.ly/iKYJLJo

11/20/2025

“Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress .... we chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable path to the GMP drug product needed for our clinical trials. We are pleased to work with AGC Biologics to advance our mission to help people enjoy longer, healthier lives.”

- Reason, CEO and co-founder, Repair Biotechnologies

11/13/2025

🧬 Breaking New Ground in Cardiovascular Therapy at AHA 2025 🧬

We’re thrilled to share that Repair Biotechnologies has presented compelling preclinical data at the American Heart Association (AHA) Scientific Sessions 2025, demonstrating that our lead candidate, REP‑0003, drives regression of established atherosclerotic plaque AFTER JUST SIX WEEKS of treatment, in mouse models.

🔍 Why does this matter?

--> REP-0003 is built on our proprietary Cholesterol Degrading Platform (CDP), designed to SAFELY break down excess intracellular free cholesterol, a key driver of plaque formation that conventional LDL-lowering therapies don’t target.

--> The effect seen in our study is rapid and plaque-regressing, marking a major leap toward treating high-unmet-need conditions such as homozygous familial hypercholesterolemia (HoFH).

--> Earlier this year, we were awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for REP-0003 in HoFH, underscoring the potential impact of this approach.

👏 Thank you to the AHA community for the platform to share our work and to our dedicated research team whose persistent efforts are translating bold science into meaningful therapeutic opportunities.

📌 What’s next?

We remain committed to advancing REP-0003 toward clinical development and to furthering our mission of treating disorders driven by toxic intracellular free cholesterol — from cardiovascular disease to metabolic dysfunction and beyond.

https://www.repairbiotechnologies.com/repair-biotechnologies-presents-preclinical-data-at-american-heart-associations-scientific-sessions-2025-showing-regression-of-atherosclerotic-plaque-with-rep-0003-treatment/

Repair Biotechnologies, Inc. today announced the recent presentation of preclinical data at American Heart Association’s (AHA) Scientific Sessions 2025, held from November 7th to 10th in New Orleans, Louisiana, supporting the ability of its drug REP-0003 to rapidly and safely reduce established at...

10/14/2025

Did you know that one of the most persistent challenges in cardiovascular disease is the toxic cholesterol INSIDE your cells?

While today’s therapies focus on lowering LDL cholesterol in the bloodstream, they don’t address the root cause: excess free cholesterol trapped within cells that drives plaque growth, inflammation, and cardiovascular risk.

At Repair, our proprietary LNP-mRNA fusion protein therapy takes a fundamentally different approach:

🧬 Selective gene delivery targets affected tissues.
⚙️ Fusion proteins are produced inside cells to degrade toxic excess free cholesterol.
💥 Cholesterol breakdown and clearance restores cell health and reverses plaque formation.

In preclinical studies, this mechanism led to rapid plaque regression, improved cardiovascular performance, and reduced inflammation – results unmatched by conventional LDL-lowering therapies.

We’re not just slowing disease progression – we’re reversing it.

10/01/2025

Have you heard about the latest in cardiovascular health?

Today’s standard of care in atherosclerosis is built around lowering risk factors: statins, PCSK9 inhibitors, ezetimibe, and others. These drugs can save lives, but they all share the same limitation: NONE address the root cause inside the artery wall.

At Repair Biotechnologies, we’re pioneering a different way to treat cardiovascular disease:

🔹 Not just lowering LDL - we target the toxic cholesterol inside cells that drives plaque growth and instability.
🔹 Complementary, not competitive - our therapy can work alongside statins or PCSK9 inhibitors to go further than risk management.
🔹 First true disease-modifying potential - aiming to regress existing plaque and stabilize arteries, not just slow new buildup.
🔹 Shifting the paradigm - from lifelong symptom control to the possibility of restoring vascular health.

Investor takeaway: We’re building what could be the first-in-class therapy to directly reverse atherosclerosis - tackling the biology that other therapies leave behind.

Don’t fall behind on the latest advancements, follow us today to learn more!

09/23/2025

Repair Bio is Part of The Future of Cardiovascular Disease Treatment

ARK Invest just highlighted how curative therapies, like gene editing, could transform cardiovascular disease (CVD), moving beyond chronic therapies such as statins and PCSK9 inhibitors.

At Repair Biotechnologies, we share that vision. Our liver-directed platform is designed to:

Target root causes of disease biology, NOT just manage LDL-C levels.
Deliver durable, disease-modifying effects, NOT just another daily pill or injection.
Unlock a massive market opportunity, addressing the world’s #1 cause of death and $500B+ in U.S. annual healthcare costs.

What’s exciting is that while ARK points to gene editing, Repair’s approach could achieve similar “one-and-done” outcomes without gene editing. We’re pioneering a differentiated path to long-lasting impact for patients suffering from severe cardiovascular and metabolic disease.

For investors, the story is clear:
👉Repair Bio is aligned with the biggest healthcare trend of the decade, curative cardiovascular innovation, while taking a unique, highly differentiated route.

Read the ARK article here for context:

Cardiovascular disease is the world’s leading killer and one of the most economically damaging, as its prevalence and costs have been rising. While statins can reduce the risk of heart attacks by ~29%, residual risk and poor long-term adherence—roughly half of patients discontinuing after a year...

06/25/2025

🧬 What is HoFH? and Why Should You Care?

HoFH is a rare genetic disease causing dangerously high LDL cholesterol from birth – often leading to HEART ATTACKS BEFORE AGE 20.

Current treatments fall short, and Repair Biotechnologies is advancing a therapy designed to functionally cure HoFH – not just manage it.

Our therapy could not only cure HoFH, but also, has the potential to help EVERYONE remove plaque build-up inside their arteries.

✔️ Orphan Disease Indication
✔️ Fast Regulatory Pathway
✔️ High-value Market
✔️ Scalable to Broader Cardiovascular Disease

🎥 Watch the video to see how we’re unlocking a major opportunity in cardiovascular care!

05/27/2025

🚨 Repair Biotechnologies Secures Orphan Drug Designation 🚨

A major milestone — and a meaningful de-risking event for their lead asset.

The FDA's Orphan Drug Designation (ODD) isn’t just a regulatory win, it’s a commercial and strategic signal that the asset targets a serious unmet need with real potential.

For investors, here’s WHY this matters:
🔹 Regulatory Advantage – Accelerated pathways and agency support
🔹 Market Protection – 7 years of U.S. exclusivity post-approval
🔹 Economic Upside – Tax credits, waived fees, potential non-dilutive funding
🔹 Valuation Catalyst – Stronger positioning for partnering and Series B conversations

This designation enhances the company’s optionality — whether toward a faster clinical path, strategic partnering, or future capital raises.

04/22/2025

🩺 What is Atherosclerosis—and can we actually reverse it?

Every 36 seconds, someone dies from cardiovascular disease.

At the heart of it? Atherosclerosis—a silent, progressive buildup of plaque inside our arteries.

But what if we could go beyond slowing it down... and actually repair the damage?

🎥 Watch our 70-second explainer to understand how Repair Biotechnologies is tackling one of the biggest health threats of our time—at the cellular level.

04/15/2025

🌟 Meet Bobby Khan, MD, PhD – Cardiovascular Trailblazer at Repair Biotechnologies ❤️‍🩹

Dr. Bobby Khan is the Chief Medical Officer at Repair Biotechnologies and a globally recognized leader in cardiology and translational medicine. With both an M.D. and a Ph.D, Dr. Khan brings a rare blend of clinical expertise and research excellence to the fight against cardiovascular diseases and aging.

🏥 He has held academic and clinical leadership roles at prestigious institutions, and has authored more than 90 scientific publications as well as has been involved in the development and implementation of numerous clinical trials addressing heart disease, metabolic disorders, and aging.

🧬 He is a co-founder of Carmel Biosciences, which was successful in receiving its first approved product by the United States Food and Drug Administration in early 2018, and at Repair Biotechnologies, Dr. Khan plays a pivotal role in translating breakthrough science into clinical strategies.

💬 Dr. Khan’s unmatched experience in cardiovascular science and clinical development helps guide Repair’s mission to tackle the root causes of age-related disease with precision and care.

04/09/2025

🌟 Meet Mourad Topors, PhD – Scientific Powerhouse Behind Repair Biotechnologies 🔬

Dr. Mourad Topors, Chief Scientific Officer at Repair Biotechnologies, brings over 20 years of groundbreaking research experience in molecular biology, aging, and cardiovascular disease. With a PhD in Molecular and Cellular Biology and a career that spans both academia and industry, Mourad has led research programs at top institutions and contributed extensively to the fields of DNA repair, cell stress responses, and degenerative disease mechanisms.

🧪 Mourad has authored numerous peer-reviewed publications and holds a strong reputation for advancing science that bridges the lab bench to real-world therapies. His deep understanding of the molecular pathways involved in aging has made him an essential part of Repair Biotechnologies’ mission to reverse the damage of age-related diseases.

👨‍🔬 Passionate about translating scientific discovery into transformative health solutions, Mourad is helping to reshape the future of medicine, one breakthrough at a time.